Pluri Inc PLUR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $1.95
- Day Range
- $1.95–1.95
- 52-Week Range
- $0.00–5.68
- Bid/Ask
- $1.89 / $1.95
- Shares Outstanding
- 10.79M
- Market Cap
- $21.04M
- Volume/Avg
- 180 / 23,515
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 16.30
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 142
- Website
- https://www.pluri-biotech.com
Valuation
|
Metric
|
PLUR
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 16.30 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
PLUR
|
|---|---|
Quick Ratio | 0.29 |
Current Ratio | 0.33 |
Interest Coverage | −28.79 |
Quick Ratio
PLUR
Profitability
|
Metric
|
PLUR
|
|---|---|
Return on Assets (Normalized) | −70.31% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −83.14% |
Return on Assets
PLUR
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|M%<LHM | LOCK|p?<K | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|Fzw>#x | LOCK|>M^VT | $71B | |||
| argenx SE ADR
ARGX
| LOCK|WtwP&W | LOCK|sk | $54B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|zFq^#>H | LOCK|CT& | $36B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|qTfKp$W | LOCK|QmVr | $36B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|pGxR^x@n | LOCK|>t@g? | $26B | |||
| Moderna Inc
MRNA
| LOCK|nZLV%@ | LOCK|p<R | $25B | |||
| Incyte Corp
INCY
| LOCK|kzkd$?S | LOCK|%L | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|vkJ%%>m | LOCK|@F% | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|Fx?&Wr& | LOCK|s> | $16B |
United States